<DOC>
	<DOCNO>NCT01089010</DOCNO>
	<brief_summary>The primary objective study demonstrate pharmacodynamic effect CK 2017357 measure skeletal muscle function fatigability patient ALS .</brief_summary>
	<brief_title>A Study CK-2017357 Patients With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>This study Phase II , double-blind , randomize , placebo-controlled , three-way crossover study CK-2017357 patient ALS . 36 72 patient randomize one six different treatment sequence . Each treatment sequence consist three dose period ; dose period¸ patient receive single oral dose placebo , 250 mg CK-2017357 , 500 mg CK-2017357 . All six treatment sequence enroll approximately number patient . A washout period least 6 day ( maximum 10 day ) employ dose patient . This study design assess effect CK-2017357 maximal voluntary muscle strength , development fatigue maximal sub-maximal voluntary muscle contraction , select pulmonary function parameter . The plasma concentration CK-2017357 measure select time point two single dos CK-2017357 men woman . The plasma concentration versus time data obtain study may use develop population PK model estimate inter-subject variability PK parameter target patient population , particular male female study patient .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Able comprehend willing sign Informed Consent Form ( ICF ) A diagnosis familial sporadic ALS ( define meeting possible , laboratorysupported probable , probable , definite criterion diagnosis ALS accord World Federation Neurology El Escorial criterion ) ( Brooks , et al. , 2000 ) Males Females 18 year age old Body mass index ( BMI ) 18.0 30.0 kg/m2 , inclusive Maximum voluntary grip strength 10 &amp; 40 pound ( female ) 10 &amp; 60 pound ( male ) Able maintain grip contraction 15 second Upright Slow Vital Capacity ( SVC ) ≥40 % predicted age , height , sex Able perform pulmonary function test Prestudy clinical laboratory finding ( include troponin I ( TnI ) CPK ) within normal range , outside normal range , deem clinically significant Investigator For female patient : The patient postmenopausal ( ≥ 1 year ) sterilize , childbearing potential , breastfeeding , pregnancy test negative , intention become pregnant course study , use contraceptive drug device . For male patient : Male patient agree duration study 10 week end study use condom sexual intercourse female partner reproductive potential female partner use additional effective mean contraception ( e.g. , diaphragm plus spermicide , oral contraceptive ) male patient must agree abstain sexual intercourse 10 week end study . Significant hepatic/renal insufficiency define Upper Limit Normal ( ULN ) laboratory finding Life expectancy &lt; 3 month Participation trial receipt investigational study drug occur within 30 day prior dose Any prior treatment CK2017357 In opinion Investigator , patient suitable participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>